

# Memorandum of Understanding

between **TheraPsil** and

**Organisation for the Prevention of Intense Suffering (OPIS)**

Date: 26 February 2021

## Purpose

TheraPsil and OPIS agree to enter into a partnership with the goal of ensuring that Canadian cluster headache patients can legally use and possess psilocybin as a therapeutic

## Background

OPIS has already been carrying out advocacy work on cluster headaches, preparing advocacy and educational materials and collaborating with other cluster headache organisations. In view of TheraPsil's success in obtaining section 56 exemptions for end-of-life patients and others to use psilocybin, and the shared ethic of trying to ensure relief of suffering for patients in great distress, OPIS proposed a partnership to help cluster headache patients in Canada.

A successful section 56 application will provide further legitimacy to the use of psilocybin as a therapeutic and expand the range of conditions for which it is recognised as having probable medical value. It will also accelerate its availability to cluster headache patients in Canada and, as a consequence, in other countries as well. This partnership will also increase recognition for both TheraPsil and OPIS as advocates for compassionate, evidence-based health policies.

## Scope

The first phase of the project involves supporting a few cluster headache patients in applying to the Minister of Health for a Section 56 exemption, including preparing the application, providing support materials and carrying out additional advocacy.

In a second phase, once the first exemptions have been accorded, the program can be expanded to offer support to more cluster headache patients in obtaining exemptions, and to take steps to normalize the treatment of cluster headaches with psilocybin through education and advocacy, including guidance to healthcare professionals.


## Responsibilities

TheraPsil will take the lead on the logistics in view of obtaining exemptions and expanding the program in Canada. OPIS will work closely with TheraPsil in providing scientific, communications and other support for the application process and accompanying advocacy. Media and other communications around a successful application will explicitly mention this partnership and all external or public communications will be pre-approved by TheraPsil's Director of Communications. OPIS will support the subsequent expansion of the program to the extent that resources allow, and also seek to leverage the success of this project for improving access in other countries.

Spencer Hawkswell

CEO, TheraPsil

Date: **February 26th 2021**

Signature: \_\_\_\_\_  


Jonathan Leighton

Executive Director, OPIS

Date: **26 February 2021**

Signature: \_\_\_\_\_  
